NASDAQ · IINN
Inspira Technologies OXY B.H.N. Ltd.
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
Loading market information…
NASDAQ · SBFM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sunshine Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sunshine Biopharma, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$3.40. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sunshine Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | -$4.40 | $8.90M |
|---|
| Q4 2024 | Mar 31, 2025 | -$10.10-10,200.0% vs estimate | $9.59M-23.25% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$9.40+99.82% vs estimate | $8.44M-28.52% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$11.00+$11.00 (0.0%)
Evoke Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.93+$0.05 (+5.09%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.89% below the high.
$1.86+$0.03 (+1.64%)
Check-Cap Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.58% below the high.
$0.83-$0.03 (-3.43%)
Lucyd, Inc’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
$1.07$0.00 (0.0%)
Acurx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.81% below the high.
$1.20+$0.06 (+5.26%)
Sonoma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.07% below the high.
$0.39+$0.02 (+4.56%)
cbdMD, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.85% below the high.
